Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer

Abstract Introduction Response Evaluation Criteria in Solid Tumors (RECIST) is the primary tool for assessing tumor response in solid tumors. Immunotherapy elicits unique response patterns, and assessment of their contribution to overall survival (OS) is of interest. We evaluated tumor size changes...

Full description

Bibliographic Details
Published in:Oncology and Therapy
Main Authors: Marina C. Garassino, Ying Cheng, Delvys Rodriguez-Abreu, Silvia Novello, Julien Mazieres, Andrew G. Robinson, Steven F. Powell, Balazs Halmos, Jhanelle E. Gray, Meihua Wang, Cong Chen, Jing Yang, Fabricio Souza, Paul Schwarzenberger, Luis Paz-Ares
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-06-01
Subjects:
Immunotherapy
NSCLC
Pembrolizumab
RECIST
Tumor response
Online Access:https://doi.org/10.1007/s40487-025-00350-6

Internet

https://doi.org/10.1007/s40487-025-00350-6

Similar Items